Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer:: results of a randomized multicenter trial.

被引：0
|
作者：
Gnant, M [1 ]
Hausmaninger, H [1 ]
Samonigg, H [1 ]
Mlineritsch, B [1 ]
Taucher, S [1 ]
Luschin-Ebengreuth, G [1 ]
Jakesz, R [1 ]
机构：
[1] Univ Vienna, Vienna, Austria
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2002年 / 76卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
12
引用
收藏
页码：S31 / S31
页数：1
相关论文
共 50 条
  • [1] Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor-Positive, Metastatic Carcinoma of the Breast in Premenopausal Women
    Carlson, Robert W.
    Theriault, Richard
    Schurman, Christine M.
    Rivera, Edgardo
    Chung, Cathie T.
    Phan, See-Chun
    Arun, Banu
    Dice, Kristine
    Chiv, Vivian Y.
    Green, Marjorie
    Valero, Vicente
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) : 3917 - 3921
  • [2] Goserelin plus anastrozole in the treatment of premenopausal hormone receptor positive, recurrent or metastatic breast cancer
    Carlson, R. W.
    Schurman, C. M.
    Rivera, E.
    Chung, C. T.
    Phan, S. C.
    Dice, E. K.
    Thomas, E.
    Valero, V.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [3] Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients
    Daisuke Shimizu
    Takashi Ishikawa
    Mikiko Tanabe
    Takeshi Sasaki
    Yasushi Ichikawa
    Takashi Chishima
    Itaru Endo
    [J]. Breast Cancer, 2014, 21 : 557 - 562
  • [4] Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients
    Shimizu, Daisuke
    Ishikawa, Takashi
    Tanabe, Mikiko
    Sasaki, Takeshi
    Ichikawa, Yasushi
    Chishima, Takashi
    Endo, Itaru
    [J]. BREAST CANCER, 2014, 21 (05) : 557 - 562
  • [5] Anastrozole and goserelin combination as first treatment for premenopausal receptor positive advanced or metastatic breast cancer: A phase II trial
    Roche, H. H.
    Thierry, D.
    Chieze, S.
    Pierre, K.
    Veyret, C.
    Abadie, S.
    Campone, M.
    Florence, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - bone density subprotocol results of a randomized multicenter trial (ABCSG-12)
    Gnant, M
    Jakesz, R
    Mlineritsch, B
    Luschin-Ebengreuth, G
    Schmid, M
    Menzel, C
    Kubista, E
    Samonigg, H
    Hausmaninger, H
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S8 - S9
  • [7] Goserelin plus anastrozole for the treatment of premenopausal women with hormone receptor positive, recurrent/metastatic breast cancer
    Carlson, RW
    Schurmann, CM
    Rivera, E
    Chung, CT
    Phan, SC
    Dice, EK
    Arun, B
    Thomas, E
    Valero, V
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S237 - S238
  • [8] Effect of anastrozole on bone mineral density: 2-year results of the 'Arimidex' (anastrozole), tamoxifen, alone or in combination trial.
    Eastell, R
    [J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2003, 18 : S312 - S312
  • [9] Switching to anastrozole plus goserelin versus continued tamoxifen for adjuvant therapy of premenopausal early-stage breast cancer: Preliminary results from a randomized trial
    Jian-wei, L.
    Guangyu, L.
    Yajie, J.
    Xia, Y.
    Zhimin, S.
    Da, P.
    Zefei, J.
    Dedian, C.
    Bin, Z.
    Binghe, X.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S315 - S315
  • [10] Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer
    Conte, Benedetta
    Poggio, Francesca
    Del Mastro, Lucia
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (13) : 1357 - 1362
12345